Loading organizations...

Disc Medicine is a technology company.
Disc Medicine has raised $140.0M across 2 funding rounds.
Key people at Disc Medicine.
Disc Medicine has raised $140.0M in total across 2 funding rounds.
Disc Medicine is a clinical-stage biopharmaceutical company developing novel therapies for hematologic diseases. Its pipeline targets various blood disorders, from rare genetic conditions to chronic anemias. The company's technical approach modulates red blood cell biology, specifically iron metabolism and heme biosynthesis, addressing underlying disease mechanisms.
Founded in 2017 by Dr. Brian MacDonald, Disc Medicine emerged from the insight that precise targeting of red blood cell biology pathways could yield transformative patient treatments. MacDonald, an experienced entrepreneur, previously founded Merganser Biotech, applying his expertise to establish Disc Medicine with a dedicated focus on advancing hematology.
Disc Medicine's therapeutic candidates address unmet needs for patients with hematologic conditions, including porphyrias, myelofibrosis, and sickle cell disease. The company’s vision is to translate scientific understanding into impactful medicines, improving lives and redefining the standard of care for blood disorders.
Disc Medicine is a clinical-stage biopharmaceutical company focused on developing first‑in‑class therapies that target fundamental pathways in red blood cell biology—principally heme biosynthesis and iron homeostasis—to treat a range of hematologic disorders, from rare genetic erythropoietic diseases to common anemias of chronic disease.[1][2]
High‑Level Overview
As a portfolio/company profile:
Origin Story
Core Differentiators
Role in the Broader Tech/Healthcare Landscape
Quick Take & Future Outlook
Quick tie‑back: Disc Medicine is a focused, clinically oriented hematology biotech that differentiates itself by pursuing human‑validated targets in iron and heme biology and advancing a multi‑modality pipeline toward treating both rare and common disorders of erythropoiesis.[2][4][3]
Sources: Disc Medicine corporate site pages on home, science, about and pipeline, and aggregated pipeline/clinical data summaries.[1][2][3][4][5]
Disc Medicine has raised $140.0M in total across 2 funding rounds.
Disc Medicine's investors include Mona Ashiya, 5AM Ventures, Access Biotechnology, Alexandria Venture Investments, Mark Chin, Atlas Venture, John Quisel, Janus Henderson Investors, Nantahala Capital Management, Novo Holdings, Rock Springs Capital, Willett Advisors.
Key people at Disc Medicine.
Disc Medicine has raised $140.0M across 2 funding rounds. Most recently, it raised $90.0M Series B in September 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 2, 2021 | Disc Medicine | $90.0M Series B | Mona Ashiya | 5AM Ventures, Access Biotechnology, Alexandria Venture Investments, Mark Chin, Atlas Venture, John Quisel, Janus Henderson Investors, Nantahala Capital Management, Novo Holdings, Rock Springs Capital, Willett Advisors |
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 2, 2021 | $90.0M Series B | Mona Ashiya | 5AM Ventures, Access Biotechnology, Alexandria Venture Investments, Mark Chin, Atlas Venture, John Quisel, Janus Henderson Investors, Nantahala Capital Management, Novo Holdings, Rock Springs Capital, Willett Advisors |
| Oct 1, 2019 | $50.0M Series A | Nilesh Kumar | ARCH Venture Partners, Atlas Venture, Foresite Capital, The Column Group, Access Biotechnology |